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Mutations in parkin cause Parkinson’s disease due
to the loss of the ubiquitin-protein ligase activity of
Parkin protein. Recent data suggest we may be
beginning to understand the nature of the proteins
that are targeted by Parkin and how these cause
neuronal damage.
The two key features of the pathology of the neurode-
generative disorder Parkinson’s disease (PD) are the
loss of subgroups of neurons in the substantia nigra
and the formation of intracellular proteinaceous inclu-
sions called Lewy bodies and Lewy neurites. A clue to
the events that drive the pathogenic process comes
from the various genetic forms of PD. Several genes
have been linked to subtly different forms of parkin-
sonism (reviewed in [1]) including α-synuclein, encod-
ing a small synaptic protein, and parkin. Parkin is one
of a large number of E3 ubiquitin-protein ligases [2],
whose cellular role is to add ubiquitin to target pro-
teins. Mutations in parkin are generally recessive,
which infers that they produce loss-of-function vari-
ants of the protein.
Several recent papers have now shown that expres-
sion of parkin is beneficial to dopaminergic neurons as
it protects them from a number of damaging events. In
this rubric of damaging stimuli we can now include the
idea of toxic proteins, whose steady-state levels in
cells have to be maintained below critical thresholds to
prevent toxic effects. Thus, Parkin can protect against
toxicity induced by mutant forms of α-synuclein [3,4]
and an endoplasmic reticulum (ER)-resident substrate
of Parkin known as pael-R [3,5]. Parkin may also facil-
itate the clearance of expanded polyglutamine proteins
that are characteristic of the triplet repeat disorders [6]
and protect against aberrant accumulation of cyclin E
[7]. In addition, Parkin is beneficial in protecting against
ER stress [5], proteasomal inhibition [4], kainic acid
‘excitotoxicity’ [7] and ceramide-induced mitochondr-
ial apoptosis [8].
Parkin and Ubiquitylation
The question arises as to how loss of parkin function
produces a disease with neuronal cell loss in selected
brain regions, or, restating the problem, how Parkin
normally protects cells from damaging events. It is of
interest that Parkin may interact with membrane pro-
teins, such as CASK, and be present at synapses [9],
thus implying a link to some neuron-specific function.
At one level the answer would appear simple: the
disease results from insufficient enzymatic activity. If
adding chains of ubiquitin molecules (ubiquitylation) to
a target protein promotes degradation via the protea-
some (Figure 1), then one might fairly assume that the
role of Parkin is to control the steady-state levels of
otherwise damaging proteins. But the answer is com-
plicated by several factors.
Firstly, there are large numbers of E3 ubiquitin-
protein ligases that control the ubiquitylation of target
proteins. The ubiquitylation machinery therefore has a
degree of redundancy, possibly allowing other E3
ligases to control protein levels when Parkin is absent.
For example, one Parkin substrate, cyclin E, can be
targeted for destruction by other modular E3 enzymes
[10]. Secondly, Parkin has been reported to target
multiple substrates, and hence it is not clear whether
the effects of loss of E3 ligase activity would mean the
accumulation of a specific substrate or a series of
substrates. Thirdly, ubiquitylation can subserve many
other functions within cells including modulation of
transcription, sorting of proteins into different cellular
compartments and synaptic development. However,
Parkin interacts directly with the proteasome [11],
suggesting that protein degradation is in fact a key
activity for Parkin. There are also a number of ubiqui-
tin-like molecules that may play similar roles to ubiq-
uitin in different protein regulation pathways, although
Parkin activity is so far only known to be directed
towards ubiquitin itself.
Having considered these caveats, the Yang paper
[3] addresses the possibility that protein degradation
is at the heart of the ability of parkin to protect cells.
The protective effect of Parkin expression on pael-r
toxicity is mediated by promoting pael-r degradation,
but Parkin-mediated protection against mutant α-
synuclein does not involve a decrease in α-synuclein
levels. This finding agrees with previous results from
in vitro studies, where α-synuclein levels were not
affected by proteasome inhibitors or expression of
Parkin [4]. Therefore, Parkin is not neuroprotective
because it ubiquitylates and promotes the bulk degra-
dation of α-synuclein, but we know that the ubiquitin-
ligase activity of Parkin is required as recessive
mutations are not neuroprotective [4]. Is it a paradox
to say that Parkin protects against a protein that it
doesn’t degrade?
I think there are two likely explanations. The simpler
of the two is that there is a species of α-synuclein that
mediates toxicity and is degraded by Parkin but is dif-
ficult to detect in cultured cells or in Drosophila. A
candidate is a glycosylated form of α-synuclein that is
present in human brain, sp22 [12]. To date, sp22 has
not been identified in any other system and it is clear
that this is a low abundance species. Until this species
is detected in a system where its formation can be
prevented, we cannot test whether this is how Parkin
protects neurons. A more complex, but perhaps more
plausible, explanation is that Parkin protects against
α-synuclein toxicity because α-synuclein promotes
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cellular damage via the same proteins that Parkin nor-
mally degrades.
Protein Aggregation and Degradation Pathways
There are several ways in which degradation of one or
more substrates may prevent α-synuclein toxicity. If
there are multiple proteins that are each marginally
damaging to cells, then the additive effect of reducing
levels of each may be beneficial. Proteins such as
pael-r used in the recent Drosophila experiments that
are directly toxic at high levels may cause neuronal
damage via ER stress (although it should be noted
that not all groups have been able to replicate the pro-
tective actions of Parkin in this model [8]). A more
interesting possibility is that a lack of Parkin activity
might cause the build-up of the total protein content
in vulnerable neurons. Increased concentration of
macromolecules within the cell could induce a ‘mol-
ecular crowding’ phenomenon, which would promote
the aggregation of α-synuclein [13]. Several lines of
evidence suggest that aggregation of α-synuclein is
toxic [14], and both pathogenic α-synuclein mutations
favour the formation of soluble, oligomeric species
[15]. Lack of Parkin activity may cause damage by
promoting α-synuclein aggregation, and increased
Parkin activity may antagonize this effect.
There are several possible subcellular targets of α-
synuclein toxicity, including mitochondria, synaptic
vesicles and the proteasome itself. We could view ER
stress, ceramide or proteasome inhibitors as ways in
which to mimic the toxic effects of α-synuclein. For
example, if α-synuclein toxicity includes damage to
mitochondria (see [16]) then the ability of Parkin to
protect against ceramide-induced mitochondrial apop-
tosis [8] may be related to this. Flies lacking parkin
expression also show mitochondrial damage [17].
All of these results suggest that Parkin has a gener-
ally neuroprotective effect that manifests itself in
dopaminergic neurons in the disease. Perhaps this
indicates a therapeutic opportunity for PD. If parkin
has such widespread utility, then molecules that
promote parkin expression or enhance its activity may
be useful in PD patients. Although Parkin activity is
not generally lacking in sporadic PD, it is still reason-
able to suggest that boosting Parkin levels would be
helpful. Experiments such as those performed in
Drosophila suggest that Parkin levels can be manipu-
lated without deleterious effects on the organism,
demonstrating the utility and validity of experiments in
model organisms as a way forward to develop new
treatments for neurological diseases.
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Figure 1. Parkin and its role in protein
degradation.
Parkin (green) has a distinct domain struc-
ture, consisting of an amino-terminal 
ubiquitin-like (Ubl) domain and two
carboxy-terminal RING domains separated
by an in-between RING (IBR) domain. The
Ubl domain has recently been reported to
interact with the proteasome, whilst the
very carboxy-terminal region interacts with
at least one membrane protein, CASK.
Parkin is therefore tethered to membranes
and may recruit proteasomes. Parkin can
also recruit a number of accessory pro-
teins such as HSP70, CHIP and compo-
nents of other modular E3 ligases such as
hsel10. The substrates of Parkin associate
with the RING1 domain and some nearby
regions, whereas the IBR and RING2
domains are responsible for binding the E2
enzyme which carries activated ubiquitin
(Ub). The proximity of E2 and substrate
may promote the ubiquitylation reaction,
which can continue through several cycles,
producing a polyubiquitylated substrate
that is recognised by the proteasome and
degraded to its constituent peptides.
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